linjc16/ctgov huggingface dataset:
High Fat Diet: Oxidative and Cardiovascular Effects

Study Overview
=================
Brief Summary
-----------------
To test the effects of a modified Atkins high fat diet on endothelial function, insulin resistance and energy balance.

Detailed Description
-----------------
To test the effects of a modified Atkins high fat diet on endothelial function, insulin resistance and energy balance.

Official Title
-----------------
High Fat Diet: Oxidative Effects and Cardiovascular Risk

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Dietary Supplement: Placebo
* Dietary Supplement: MUFA
* Dietary Supplement: PUFA
* Dietary Supplement: SFA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI 30-39.9 Female Age 21-40 Exclusion Criteria: Smoker Comorbid Disease

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: AFN A<br>High Fat Diet Placebo | Dietary Supplement: Placebo<br>* Placebo<br>|
| Experimental: AFN B<br>MUFA | Dietary Supplement: MUFA<br>* MUFA<br>|
| Experimental: AFN C<br>PUFA | Dietary Supplement: PUFA<br>* PUFA<br>|
| Experimental: AFN D<br>SFA | Dietary Supplement: SFA<br>* SFA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| endothelial function |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| energy balance and body composition |  | 4 months |
The Prognostic Assessment of Extubation in Aged Patients With Multiple Organ Dysfunction Syndrome

Study Overview
=================
Brief Summary
-----------------
The multiple organ dysfunction syndrome (MODS) has remained the major factor contributing to prolongation of intensive and mortality. It is reported that the mortality rates have varied between 20% and 100%, depending on number, severity, duration, type and combination, and definition of dysfunction. In our study, the investigators explore some comprehensive treatment technology to improved outcomes of MODS patients.

Official Title
-----------------
Key Technology Research of the Comprehensive Treatment of Multiple Organ Dysfunction Syndrome

Conditions
-----------------
Multiple Organ Dysfunction Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 60 years old; presence of altered organ function in an acutely ill patient such that homeostasis cannot be maintained without intervention; have trachea intubation after admitting to intensive care unit within 24 hours. Exclusion Criteria: end stage multiple organ failure.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the prognostic assessment of aged patients with MODS | According to the outcomes of 28-day,all the enrolled patients were divided into survival group and death group, clinical datum of which were collected and analysed. And then these prognosis were evaluated with the current scoring systems [(Acute Physiology and Chronic Health EvaluationⅡ(APACHEⅡ, APACHE Ⅲ), Sample Acute Physiological score(SAPSⅡ), Multiple Organ Dysfunction score(MODS)], the predictive power of which were compared by receiver operating characteristic(ROC) curve. Finally, a binary logistic regression analysis was performed to evaluate the concerning prognostic factors of MODSE. | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
MODS, invasive mechanical ventilation, Aged, Multiple organ failure, Extubation, Prognosis
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain

Study Overview
=================
Brief Summary
-----------------
The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

Official Title
-----------------
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population

Conditions
-----------------
Dyslipaemia, Atherosclerosis Risk, Increased hsCRP, Inflammatory and Oxidative Status in the Spanish Population

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have an Informed consent form signed when the patient accepted to participate in the study already performed. Spanish population between Data from Epidemiological studies performed after the year 2000 Exclusion Criteria: Spanish population outside the age range Data from Epidemiological studies performed before the year 2000

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lipid fractions: high-density lipoprotein, low-density lipoprotein, and total cholesterol, and triglycerides, and dislipidemia treatments |  | retrospectively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High sensitivity C reactive protein & CHR risk by Framingham adapted functions |  | retrospectively | 
| Lipid profile among the Spanish regions, as in the primary outcome variable |  | retrospectively | 
| Biomarkers: Interleukines 6 and 10, oxidized LDL, VCAM, ICAM, TNF alpha, neopterin, fibrinogen, lp(a), MMP 9 Apo A, Apo B, adiponectin, leptin, resistin, and yet other |  | prospectively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dyslipaemia, atherosclerosis risk, increased hsCRP, inflammatory and oxidative status in the Spanish population
Forced Oscillations for Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation

Study Overview
=================
Brief Summary
-----------------
A study to evaluate the role of forced oscillations in diagnosis of bronchiolitis obliterans syndrome in patients after bone marrow transplantation. The force oscillations technique will be compared with classical spirometry.

Official Title
-----------------
Functional Evaluation of Distal Airways by Forced Oscillations: Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation

Conditions
-----------------
Bronchiolitis Obliterans, Bone Marrow Transplantation

Intervention / Treatment
-----------------
* Other: Forced oscillations measure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years Bone marrow or hematopoietic stem cells transplantation for more than 100 days Clinical stability Patients affiliated to a social security system Patients having given his (her) written consent. Exclusion Criteria: Bronchiolitis Obliterans already diagnosed Unresolved Respiratory infection Unresolved mechanical complication (pneumothorax, effusions) Medicinal pneumopathy Inability to perform pulmonary function tests

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>Patients with bronchiolitis obliterans syndrome after bone marrow transplantation | Other: Forced oscillations measure<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of days | Temporal difference between the date of the functional change measured by the technique of the forced oscillations and by the standard techniques of plethysmography. | 2 years |
Patient Perceptions and Willingness to Enroll in Clinical Trials

Study Overview
=================
Brief Summary
-----------------
The objective of our study is to determine which factors affect willingness to participate in gynecologic oncology clinical trials. Women with a diagnosis of gynecologic malignancy will be approached to complete a survey assessing willingness to participate in clinical trials. The validated Attitudes and Randomized Trials Questionnaire (ARTQ) will be used to assess willingness to participate.

Official Title
-----------------
Patient Perceptions and Willingness to Enroll in Clinical Trials

Conditions
-----------------
Cancer, Clinical Trials

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of gynecologic malignancy English or Spanish literate Exclusion Criteria: Prior enrollment in a clinical trial Currently pregnant Currently incarcerated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Population<br>Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials. | Other: Survey<br>* Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Willingness to Participate in Clinical Trials | Bivariate outcome derived from ARTQ survey | 6 months |
Effect of Stress on Heroin-Related Memory Retrieval

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether cortisol and propranolol are effective in the modulation of stress induced heroin-related retrieval enhancement.

Conditions
-----------------
Heroin Dependence, Learning and Memory

Intervention / Treatment
-----------------
* Drug: propranolol and cortisol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants had to have met DSM-IV criteria for heroin dependence prior to abstinence. Exclusion Criteria: current use of any medications; current DSM-IV diagnosis of any affective, anxiety, or psychotic disorder; current dependence on any substance besides heroin and nicotine (based on DSM-IV criteria); or risk factors for untoward side effects from propranolol and cortisol (i.e., irregular heartbeats, history of cardiogenic shock, history of severe heart failure, asthma, fungal Infections, hyperlipidemia, history of hypertension, or abnormal ECG or other laboratory findings).

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A, 4<br> | Drug: propranolol and cortisol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucocorticoids enhanced heroin-related memory retrieval in abstained heroin addicts |  |  |
Venous Thrombosis in Turner Syndrome

Study Overview
=================
Brief Summary
-----------------
In the literature, cases of thrombosis in the venous system have been described in girls and women with Turner syndrome. By screening a group of women with Turner syndrome, the researchers wish to find out if this condition is more frequent in this patient population.

Detailed Description
-----------------
In the literature cases of thrombosis in the venous system has been described in girls and women with Turner syndrome. By screening a group of women with Turner syndrome we wish to find out if this condition is more frequent in this patient population. Participants are examined with screening blood tests evaluating thromboembolic disturbances.

Official Title
-----------------
The Risk of Venous Thrombosis in Women With Turner Syndrome

Conditions
-----------------
Thromboembolic Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Turner syndrome verified by karyotyping Aged 18 or above Exclusion Criteria: Malignant disease Treatment with anticoagulants

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TS<br>Women with Turner syndrome | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Turner syndrome, Thromboembolic disease
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation

Study Overview
=================
Brief Summary
-----------------
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates. Patients will be followed including protocol biopsy at 1, 12, 36, 60 month posttransplant, regular nuclein acid testing (NAT) for cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK virus (BKV) in urine and blood. The investigation is undertaken to clarify the reason for equal survival rates for patients on cyclosporine and tacrolimus despite the lower rejection rate on tacrolimus.

Detailed Description
-----------------
Special attention will be paid to the epidemiology of virus infections behind one year post transplant. Very limited data are available on this issue and there is suspicion that tacrolimus patients suffer more hard with viruses like CMV, EBV, BKV. These viruses can induce graft nephropathy and threat to the life of the recipient.

Official Title
-----------------
Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients

Conditions
-----------------
Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy

Intervention / Treatment
-----------------
* Drug: cyclosporine or tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first kidney allograft recipients alemtuzumab induction Exclusion Criteria: CNI intolerance

Ages Eligible for Study
-----------------
Minimum Age: 6 Months
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cyclosporine group<br>cyclosporine group - after alemtuzumab induction cyclosporine was administered | Drug: cyclosporine or tacrolimus<br>* after alemtuzumab, cyclosporine or tacrolimus was administered<br>|
| tacrolimus group<br>tacrolimus group - after alemtuzumab induction tacrolimus was administered | Drug: cyclosporine or tacrolimus<br>* after alemtuzumab, cyclosporine or tacrolimus was administered<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient Survival | in cyclosporine group 96.4 +/- 2.8%; in tacrolimus group 96.3 +/- 3.4% | 5 years | 
| Graft Survival | in cyclosporine group 84.6 +/- 5.8%; in tacrolimus group 86.2 +/- 4.1% | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rejection, survival, alemtuzumab, cyclosporine, tacrolimus
The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients

Study Overview
=================
Brief Summary
-----------------
According to Morgan et. al. (J Neurosurg 101:1026-1029, 2004): bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs, we're going to test the hypothesis in the cerebrospinal fluid of spontaneous subarachnoid hemorrhage patients.

Detailed Description
-----------------
According to Morgan et. al. (J Neurosurg 101:1026-1029, 2004): bilirubin as a cerebrospinal fluid marker of sentinel subarachnoid hemorrhage: a preliminary report in pigs, we're going to test the hypothesis in the cerebrospinal fluid of spontaneous subarachnoid hemorrhage patients. We'll collect the serial cerebrospinal fluid in 15-20 spontaneous subarachnoid hemorrhage patients to see the time sequence of changes in bilirubin levels.

Official Title
-----------------
The Bilirubin Levels in Cerebrospinal Fluid of Spontaneous Subarachnoid Hemorrhage Patients

Conditions
-----------------
Spontaneous Subarachnoid Hemorrhage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spontaneous subarachnoid hemorrhage in less than three days Exclusion Criteria: spontaneous subarachnoid hemorrhage more than three days

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy

Study Overview
=================
Brief Summary
-----------------
Researchers want to compare proton stopping ratios, used for proton beam therapy planning, calculated based on single energy CT and dual energy CT images; with the intension of improve upon the proton range determination.

Detailed Description
-----------------
The main goal of this study is to compare proton stopping ratios, used for proton beam therapy planning, calculated based on single energy CT and dual energy CT images. The calculation methods for proton stopping power ratios differs for the two types of CT images, and researchers want to investigate if the proton stopping power ratio can be estimated more accurately by using dual energy CT. A more accurate stopping power ratio calculation gives a more accurate proton range determination in the patient tissue, which again will lead to a better knowledge of the dose distribution in the patient undergoing cancer treatment with proton beam irradiation. Knowing the accurate dose distribution allows for an uncertainty margin reduction around the tumor, which will result in less normal tissue being irradiated and thereby the risk of side effects is reduced without risking an under-dosage of the tumor.

Official Title
-----------------
Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cancer patients who are scheduled for a control CT scan Exclusion Criteria: Under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention will be done|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stopping power ratio differences | For each patient the stopping power will be calculated based on both single and dual energy CT. The treatment of the patient will not be affected in any way of this study, the patient will receive the same treatment whether or not the patient volunteers to participate in this study. And the outcome of the calculations performed in this study will have no influence for the patient. The calculations of the stopping power differences for each patient will as far as possible be done right after acquisition of the CT images, but the exact time point is not important. We will set as a deadline that the calculation for each patient is done within 2 months of acquisition of the CT images of the patient. The entire study will be finished within 2 years, and the results will be tried published in a peer-reviewed journal. | 2 months |